239 related articles for article (PubMed ID: 24271420)
1. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
Tao L; Huang G; Shi S; Chen L
Med Oncol; 2014 Jan; 31(1):777. PubMed ID: 24271420
[TBL] [Abstract][Full Text] [Related]
2. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.
Shi S; Tao L; Song H; Chen L; Huang G
APMIS; 2014 May; 122(5):380-91. PubMed ID: 24628659
[TBL] [Abstract][Full Text] [Related]
4. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
5. The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma.
Wei C; Wang W; Pang W; Meng M; Jiang L; Xue S; Xie Y; Li R; Hou Z
Tumour Biol; 2014 Mar; 35(3):1997-2007. PubMed ID: 24104501
[TBL] [Abstract][Full Text] [Related]
6. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant cytokine-induced killer cell immunotherapy improves long-term survival in patients with stage I-II non-small cell lung cancer after curative surgery.
Huang J; Zhao X; Zhang Z; Yang S; Chen X; Shen C; Wang L; Qi Y; Zhang Y
Cytotherapy; 2023 Feb; 25(2):202-209. PubMed ID: 36379882
[TBL] [Abstract][Full Text] [Related]
8. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients.
Yang L; Ren B; Li H; Yu J; Cao S; Hao X; Ren X
Cancer Immunol Immunother; 2013 Jan; 62(1):65-73. PubMed ID: 22744010
[TBL] [Abstract][Full Text] [Related]
10. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.
Zhao P; Bu X; Wei X; Sun W; Xie X; Li C; Guo Q; Zhu D; Wei X; Gao D
Int Immunopharmacol; 2015 Apr; 25(2):450-6. PubMed ID: 25698555
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer.
Wang M; Cao JX; Pan JH; Liu YS; Xu BL; Li D; Zhang XY; Li JL; Liu JL; Wang HB; Wang ZX
PLoS One; 2014; 9(11):e112662. PubMed ID: 25412106
[TBL] [Abstract][Full Text] [Related]
13. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
14. Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study.
Han Y; Mu D; Liu T; Zhang H; Zhang J; Li S; Wang R; Du W; Hui Z; Zhang X; Ren X
Thorac Cancer; 2021 Jan; 12(2):145-152. PubMed ID: 33150733
[TBL] [Abstract][Full Text] [Related]
15. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells.
Dalla Pietà A; Cappuzzello E; Palmerini P; Ventura A; Visentin A; Astori G; Chieregato K; Mozzo V; Perbellini O; Tisi MC; Trentin L; Visco C; Ruggeri M; Sommaggio R; Rosato A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272306
[TBL] [Abstract][Full Text] [Related]
16. CIK cell-based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer.
Lin XR; Zhou XL; Feng Q; Pan XY; Song SL; Fang H; Lei J; Yang JL
J Cancer Res Clin Oncol; 2019 May; 145(5):1123-1132. PubMed ID: 30796510
[TBL] [Abstract][Full Text] [Related]
17. Discovering single cannabidiol or synergistic antitumor effects of cannabidiol and cytokine-induced killer cells on non-small cell lung cancer cells.
Li Y; Sharma A; Hoffmann MJ; Skowasch D; Essler M; Weiher H; Schmidt-Wolf IGH
Front Immunol; 2024; 15():1268652. PubMed ID: 38558822
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy with sequential cytokine-induced killer (CIK) cells in stage IB non-small cell lung cancer.
Li DP; Li W; Feng J; Chen K; Tao M
Oncol Res; 2015; 22(2):67-74. PubMed ID: 25706393
[TBL] [Abstract][Full Text] [Related]
19. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
